Shares of Intra-Cellular Therapies Inc (NASDAQ:ITCI) have earned a consensus rating of “Hold” from the seven research firms that are covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $31.75.
A number of analysts have recently commented on the company. ValuEngine raised Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a research note on Friday, March 1st. Zacks Investment Research lowered Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a research note on Thursday, December 20th. BidaskClub raised Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a research note on Thursday, February 14th. Finally, Canaccord Genuity set a $31.00 price target on Intra-Cellular Therapies and gave the company a “buy” rating in a research note on Wednesday, December 12th.
Get Intra-Cellular Therapies alerts:In other news, EVP Michael Halstead sold 3,108 shares of the firm’s stock in a transaction dated Monday, January 7th. The stock was sold at an average price of $12.42, for a total transaction of $38,601.36. Following the completion of the transaction, the executive vice president now directly owns 24,757 shares in the company, valued at $307,481.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Kimberly E. Vanover sold 9,564 shares of the firm’s stock in a transaction dated Friday, January 4th. The stock was sold at an average price of $11.47, for a total value of $109,699.08. Following the transaction, the senior vice president now owns 37,224 shares of the company’s stock, valued at $426,959.28. The disclosure for this sale can be found here. Insiders have sold 113,209 shares of company stock worth $1,301,080 over the last three months. Insiders own 17.40% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of the company. Geode Capital Management LLC raised its position in shares of Intra-Cellular Therapies by 5.1% during the fourth quarter. Geode Capital Management LLC now owns 524,461 shares of the biopharmaceutical company’s stock worth $5,973,000 after acquiring an additional 25,588 shares during the last quarter. Norges Bank bought a new position in shares of Intra-Cellular Therapies during the fourth quarter worth about $3,759,000. Dimensional Fund Advisors LP raised its position in shares of Intra-Cellular Therapies by 1.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,444,223 shares of the biopharmaceutical company’s stock worth $16,450,000 after acquiring an additional 24,335 shares during the last quarter. General American Investors Co. Inc. bought a new position in shares of Intra-Cellular Therapies during the fourth quarter worth about $3,416,000. Finally, Macquarie Group Ltd. raised its position in shares of Intra-Cellular Therapies by 42.5% during the fourth quarter. Macquarie Group Ltd. now owns 74,816 shares of the biopharmaceutical company’s stock worth $852,000 after acquiring an additional 22,300 shares during the last quarter. Institutional investors own 69.73% of the company’s stock.
NASDAQ:ITCI traded up $0.11 during trading hours on Friday, hitting $12.68. The company’s stock had a trading volume of 13,329 shares, compared to its average volume of 338,466. The firm has a market capitalization of $685.17 million, a PE ratio of -4.44 and a beta of 1.24. Intra-Cellular Therapies has a twelve month low of $10.21 and a twelve month high of $25.82.
Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings data on Wednesday, February 27th. The biopharmaceutical company reported ($0.75) earnings per share for the quarter, beating the consensus estimate of ($0.91) by $0.16. As a group, sell-side analysts anticipate that Intra-Cellular Therapies will post -3.93 EPS for the current fiscal year.
Intra-Cellular Therapies Company Profile
Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders.
Further Reading: What is a Roth IRA?
No comments:
Post a Comment